Zydis en es it fr

Categoria

Zydis Nombres de marca, Zydis Analogos

Zydis Marca los nombres de mezcla

  • No information avaliable
  • Zydis Formula quimica

    C17H20N4S

    Zydis RX enlace

    http://www.rxlist.com/cgi/generic3/symbyax.htm

    Zydis FDA hoja

    Zydis FDA

    Zydis MSDS (hoja de seguridad de materiales)

    Zydis Sintesis de referencia

    JK Chakrabarti et al., Patente de EE.UU.. 5,229,382 (1991)

    Zydis Peso molecular

    312.434 g/mol

    Zydis Punto de fusion

    195oC

    Zydis H2O Solubilidad

    No hay información disponible

    Zydis Estado

    Solid

    Zydis LogP

    2.199

    Zydis Formas de dosificacion

    Tablet (oral)

    Zydis Indicacion

    Para el tratamiento de la esquizofrenia y el trastorno maníaco depresivo (trastorno bipolar).

    Zydis Farmacologia

    La olanzapina, un antipsicótico atípico, se usa para tratar tanto los síntomas positivos y negativos de la esquizofrenia, manía aguda con trastorno bipolar, la agitación y los síntomas psicóticos en la demencia. Futuro usos pueden incluir el tratamiento de trastorno obsesivo-compulsivo y trastornos graves de conducta en el autismo. Estructural y farmacológicamente similar a la clozapina, la olanzapina se une a la alfa (1), la dopamina, , La histamina H1, muscarínicos, y la serotonina tipo 2 (5-HT 2) receptores.

    Zydis Absorcion

    Se absorbe bien, aproximadamente el 40% de la dosis metabolizada antes de alcanzar la circulación sistémica.

    Zydis Toxicidad

    No hay información disponible

    Zydis Informacion de Pacientes

    PATIENT INFORMATION

    Physicians are advised to discuss the following issues with patients for whom they prescribe
    olanzapine:

    Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
    especially during the period of initial dose titration and in association with the use of
    concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
    or alcohol.

    Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
    impair judgment, thinking, or motor skills, patients should be cautioned about operating
    hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
    therapy does not affect them adversely.

    Pregnancy: Patients should be advised to notify their physician if they become pregnant or
    intend to become pregnant during therapy with olanzapine.

    Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.

    Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
    or plan to take, any prescription or over-the-counter drugs, since there is a potential for
    interactions.

    Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.

    Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
    overheating and dehydration.

    Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
    (0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).

    Laboratory Tests

    Periodic assessment of transaminases is recommended in patients with significant hepatic disease.

    Zydis Organismos afectados

    Humanos y otros mamíferos